3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
5
Phase 2
3
Phase 1/2
2
Phase 2/3
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Neuroectodermal Tumors
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Brain Neoplasms
1
Interventions
Cyclophosphamide
624
pembrolizumab
500
Paclitaxel
456
Gemcitabine
438
Carboplatin
435
Cisplatin
418
Radiotherapy
380
fludarabine
365
Nivolumab
340
Docetaxel
277
Bevacizumab
276
Irinotecan
257
Magnetic Resonance Spectroscopy
242
Fluorouracil
228
Dexamethasone
225
Specimen Handling
221
Capecitabine
218
Rituximab
205
Cytarabine
201
Oxaliplatin
200
Ipilimumab
199
Temozolomide
197
Biopsy
196
fludarabine phosphate
194
Etoposide
181
Lenalidomide
176
Doxorubicin
175
Leucovorin
173
Cetuximab
171
Injections
170
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Interventional
×
Oncolytic Virotherapy
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled